BiotechTube

Vixarelimab + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prurigo Nodularis

Conditions

Prurigo Nodularis, Pruritis

Trial Timeline

Mar 11, 2019 → Aug 24, 2023

NCT ID
NCT03816891

About Vixarelimab + Placebo

Vixarelimab + Placebo is a phase 2 stage product being developed by Kiniksa Pharmaceuticals for Prurigo Nodularis. The current trial status is completed. This product is registered under clinical trial identifier NCT03816891. Target conditions include Prurigo Nodularis, Pruritis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03816891Phase 2Completed

Competing Products

20 competing products in Prurigo Nodularis

See all competitors
ProductCompanyStageHype Score
UpadacitinibAbbVieApproved
85
Pimecrolimus + Hydrocortisone + PimecrolimusNovartisPhase 2
52
Rocatinlimab + PlaceboAmgenPhase 3
76
AbrocitinibPfizerPhase 2
51
Dupilumab SAR231893 (REGN668)SanofiPre-clinical
22
DupilumabSanofiPhase 3
76
DupilumabSanofiPre-clinical
22
DupilumabSanofiPre-clinical
22
Ruxolitinib Cream 1.5%IncytePhase 1
30
Ruxolitinib Cream + Vehicle CreamIncytePhase 3
74
INCB054707 + PlaceboIncytePhase 2
49
Povorcitinib + PlaceboIncytePhase 3
74
Povorcitinib + PlaceboIncytePhase 3
74
Ruxolitinib Cream + Vehicle CreamIncytePhase 3
74
CDX-0159 + Normal salineCelldex TherapeuticsPhase 1
28
barzolvolimabCelldex TherapeuticsPhase 2
47
nalbuphine HCl ER tablets 90 mg BID + nalbuphine HCl ER tablets 180 mg BID + Placebo tablets BIDTrevi TherapeuticsPhase 2/3
60
nalbuphine HCl ERTrevi TherapeuticsPhase 2/3
60
Nalbuphine ER Tablets + Placebo TabletsTrevi TherapeuticsPhase 2/3
60
serlopitant + PlaceboVyne TherapeuticsPhase 2
44

Other Products from Kiniksa Pharmaceuticals

Rilonacept + PlaceboPhase 3
72
KPL-387 + PlaceboPhase 2/3
60
mavrilimumabPhase 2/3
60
Mavrilimumab + PlacebosPhase 2
47
Mavrilimumab + PlacebosPhase 2
47